Infants and children differ pharmacologically from adults because the progressive maturation of various systems during development leads to variations in drug action and dosage. These differences are reviewed. Pharmacogenetic factors which affect anaesthesia and the problems of drug overdosage, as seen in paediatric intensive care units, are briefly considered.
plasma protein binding, circulatory factors, the degree of development of the blood brain barrier and drug specificity for tissue or cell.
(a) Body Water. Total body water constitutes over 80 per cent of body weight in the foetus. It is 75-80 per cent at birth and decreases to 60 per cent body weight during the first two years. The body water compartments change from a relatively large extracellular volume in the newborn to a larger intracellular compartment by the end of the first year (Table 1 ) (Friis Hansen 1971) . Thereafter the extracellular fluid constitutes 20-25 per cent of body weight (Cheek 1961) and its ratio to total body water remains fairly constant (Mellits and Cheek 1968) . Sodium replacement in hyponatraemia and the dose of sodium bicarbonate required in the treatment of metabolic acidosis should be relatively greater in the infant because of the relatively larger extracellular volume in which it will be distributed. The formula commonly employed in adults is : 0·3 X Body weight X Deficit in mEqjl.
In the neonate 0·5 and in the infant under six months 0·4 should be used instead of 0·3 in this formula.
(b) Protein Binding. The protein binding of a drug depends on factors such as the affinity of the drug for the binding site, pH, pKa, the concentration of the drug and its duration of action. There are conflicting reports on plasma protein patterns in infants but it appears that T. C. K. BROWN albumin levels are lower in the newborn and reach adult values within the first year, except in premature infants where serum albumin is even lower initially and takes longer to reach mature levels (Rehrendt J 962, O'Brien, Ibbott and Rogerson ]968, Jackson 19fil).
These differences would influence protein binding of drugs predominantly bound to albumin.
Displacement of bilirubin from protein binding sites lllay be caused by salicylates, sulphadimet hoxine (:\!adribon), sulphisoxazole (Gantrisin) and sulphadiazine (J olll1son et al. (c) CClltral Xal'olls Systcm. Developlllent of the" blood brain barrier" is incomplete in the newborn and as a result there is increased permeability of certain substances into the brain. :\! velination is incomplete in the newborn brain, and it has been shown that the differences in distribution of radio-active phenobarbitone in the brains of newborn kittens compared with adult cats correlated with the degree of myelin dewlopment (Domek, Barlow and Roth 19ti4) . Studies in rats and rabbits have shown more prolonged effects and increased toxicity of pentobarbitone (\\'eatherall HJ60) and morphine (Kupferherg and \\'ay 19(8) in young animals due to increased brain penetration.
Roth, Delgardo and Giarman (l9fHi) suggested that more rapid brain penetration of the basal intravenous anaesthetic gammahydroxybutyrate could account for its more rapid onset of action in the \'oung than in adults. Ressman and Skolnik . (l9()4) suggested, on the basis of rat studies, that the delayed onset of action of gammahydroxybutyrate is due to metabolic transformation to an active metabolite, gammabutyrolactone. However, relatively rapid onset of sleep occurs in children up to at least six years of agc--an age when brain development is well advanced and when the "blood brain harrier" is fun ctional.
In practice, hased on these and similar findings (Done 19()4), intravenous barbiturates arc avoided as induction agents during the neonatal period, and morphine and other narcotics are usuallv not ernplo~'ed under six months of age, and between six and 12 months it is recommended that the\' are used in reduced dosage (0 ·lmg/kg ll10rplline compared with ()·2 mg!kg morphine from one year onwards).
Receptors
(a) XeuroJlluscular.
~euromuscular transmission in the newborn is similar to that in the adult except that post-tetanic exhaustion (decreased twitch height after tetanus) may occur (Churchill Davidson and Wise 19()3, 19(4) , partiCUlarly in premature infants and during the first two weeks of life. This phenomenon is sometimes seen in patients with myasthenia gravis. Electromyographic studies have shown that features of a desensitizing block are common in premature infants and neonates following depolarizing relaxants (Churchill Davidson and \Vise 19H; 3) .
A given dose of suxamethonium based on weight has a more transient effect in the newborn (Kightingale et al. 19(6) . Telford and Keats (19")7) found that the dose required to maintain apnoea for the duration of anaesthesia in the neonate was 450 f1.g/kg/min compared with the adult dose of 90 f1.g/kg/min. The dose decreased rapidly after the neonatal period, but the requirements at six years were still greater than for an adult. \Vhen surface area is used for the calculation of dosage, \\'alts and Dillon (J 9(9) found no difference in the dose of suxamethonium with age. The relatively greater surface area to body weight ratio in the newborn and differences in the extracellular fluid volume probably account at least partly for the apparent difference in response between neonates and mature subjects. The newborn thus requires a larger dose per kg than the adult to produce a comparable effect. Suxamethonium O· 4 mg/kg will paralyse 9.5 per cent of adults for two to three minutes (Thesleff 1952) .
A practical intravenous dose of suxamethonium for intubation in newborns is 2 mg/kg. Low cholinesterase levels are found in neonates but do not seem to prolong the action of suxamethonium (Stead 1 9))i")).
The dose requirements for non-depolarizing relaxants are reduced in the neonate. Bush and Stead (19ti2) found that one-day-old infants required an average of 0 ·32 mg/kg d-tubocurarine to produce adequate control of ventilation and satisfactory operating conditions.
The dose increased to o· M"i mg/kg by 10 days and O· f,5 mg/kg at one month. Under normal conditions children over three months tolerate the full dose of O· 6() mg/kg, but exceptions to this occur in children with severe burns and those with cyanotic congenital heart disease who are relatively resistant to non-depolarizing relaxants and may require as much as 1 mg/kg d-tubocurarine to produce the usual degree and duration of relaxation. Because the response AlZaest11~sia and Intensive Care, Vol. I, 1\'0. G, jI,'ovel11bel', 1!17.3 to non-depolarizing relaxants alters during the neonatal period and the newborn is sensitive to these drugs, the safest approach is to give 0·2 mg/kg d-tubocurarine initially and then give further increments of one-quarter to onehalf of this as necessary to produce satisfactory relaxation. This will usually be about 0·3 mg/kg in the first day, but the initial dose suggested produces sufficient relaxation to allow easy atraumatic intubation without complete respiratory paralysis.
Some antibiotics potentiate non-depolarizing muscle relaxants when given intraperitoneally. The newborn may be more susceptible to the relaxant properties of some of these drugs and two infants paralysed following accidental overdo sage with colistin (colymycin) have been treated in the intensive care unit at the Royal Children's Hospital, Melbourne.
(b) A utollomic. The concept of physiological vagotonia in newborns is not now generally accepted, but infants and small children appear to have increased responsiveness to vagal stimulation (Lipton, Steinschneider and Richmond 1965) . Bradycardia is common in children during anaesthesia when suxamethonium (Leigh et al. 1957 ) and deeper levels of anaesthesia with halothane or cyclopropane are used. Reflex bradycardia occurs on intubation and in response to a variety of surgical stimuli including particularly traction on the medial and lateral rectus muscles during strabismus surgery-the oculo-cardiac reflex is more potent in young children. These reflexes can be blocked with atropine in dosages (0'1-0'2 mg in the neonate) far greater than the amount required to suppress salivation or prevent bradycardia. Unna et al. (1950) determined the minimal effective dose to su ppress salivation and found that it was 5-10 times less than the dose usually recommended for premedication in neonates. The findings in their study did not support the idea that infants are relatively resistant to atropine.
The dose of atropine commonly used for premedication varies widely. The lowest dose employed is 10 [J.g/kg, but commonly a dose adjusted for age and taking into account the changing ratio of surface area to body weight is used. The neonatal dose is 50 [J.gjkg, decreasing to 35 iJ.gjkg at one year and 25 [J.gjkg at eight years (Stocks 1972) . Although these doses may be higher than necessary, they are unlikely to produce toxic effects under normal conditions. The dose of atropine employed to counteract the muscarinic effects of neostigmine during reversal of non-depolarizing relaxants also varies widely. Stocks (1965) studied the vascular responses in puppies and found that electrical stimulation of the sympathetic nerves to the hind limb produced vasodilatation during the first two weeks and then the vasoconstrictor response progressively increased after four weeks. The vasoconstrictor responses to intra-arterial adrenaline and nor-adrenaline were similar and reached a maximum at four weeks-these were significantly greater than the responses at one day and in the adult. There is a progressive decrease in duration of response to intra-arterial adrenaline and noradrenaline with age. The findings during early life fit in with the observation that systemic blood pressure is low in neonates.
Adrenaline is an extremelv useful agent in the resuscitation of children' following cardiac arrest. Children tolerate relatively large doses and it rarely causes ventricular fibrillation. The dose of 50 [J.gjkg in the neonate, reducing to 20 [J.g/kg in an eight year old, has proved effective in the management of cardiac arrest (Stocks 1972) .
Metabolism
Most drug metabolic pathways which have been studied in the neonatal period have been found to be deficient (Done 1964) . "Phase!" detoxification processes such as oxidation, Anaesthesia and Tlltensive Care, Vol. T, ,"10. 6, November, Un.1 reduction and hydrolysis may have to take place before " Phase ~ " (conjugation) reactions can occur. It ma\' he difficult to estahlish in the tml-stagc process which step is defective. H ydrok;is seems to differ little hetween neonates and adults, but reduction reactions are slower, hut not as slow as oxidations.
Enznl1e deficienn' may lead to toxicit\·. The iack of glucU'ronyl" transferase in tl;e newborn is responsible for the delayed elimination of chloramphenicol, which can result in overdosage and the development ultimately of an ashen grey cyanosis termed the "grey syndrome" (Kent, Tucker and Taramenko 1 !I(iO; :'IIichael and Sutherland 1960; Ra\'nsford HII);)). In the newborn, clinical features of toxicity deyelop with doses of 100 mg/kg per day, so that it is advisable to decrease the dose to GO rng/kg per day in the new horn and ~5 rng/kg per da\' in a premature infant. The ,;ensitivit~· to chloramphenicol usually disappears by one month when the levels of glucuronyl transferase increasc and renal function has improvcd.
Some drugs are inactin' until metabolized to an active metaholite. The lack of enzvmes involved will protect the newborn ag~ainst toxicity of these drugs. A.n example is codeine, which depends for its activity on conversion to morphine (Poe, Strong and \\'itt 19;)7).
Drugs which have heen shown experimentally in rats, mice, rabbits or guinea-pigs to \w metabolizcd more slowly in the newborn havc been summarized by D~me (1 !Hi4) and include hexobarbitone (oxidation), amphetamine (deamination), codeine, phenacetin (clealkylation), promazine and chlorpromazine (sulphoxidation).
Metabolism of pethidine is also impaired (Rudofsky' and Crawford HHiti) . There is evidence that a variety of pathways exist for glucuronidation so that ester and ether linkages are formed by a different enzyme system to N-linked glucuronidation (Done HI(4) .
The enZ\'mes involved are deficient in the newborn (In~coe and Axelrod 19(0).
As well as finding slower metabolism of para-amino-benzoic acid in newborn infants, Vest and Salzberg (H165) found that there was a qualitatiw difference in the pattern of metaholites between newborns and older children.
The former excrete mainly acetyl para-amino-benzoic acid but after eight weeks glycine conjugates (para-aminohippuric acid) become predominant.
Some enzymes can be induced in the newborn. Phenobarbitone injections for three or four days in newborn rabbits increase the metabolism of 'hexobarbitone, aminopyrene and para-nitro-benzoic acid (Hart et al. 19(2) . Glucuronyl transferase activity can be increased by benzpyrene treatment.
There is conflicting evidence for the value of phenobarbitone as an enzyme inducer to stimulate glucuronidation of bilirubin in the newborn (Behrman and Fisher 1971) . It requires about three days' treatment before the beneficial effect is observed, so that treatment would have to hegin in IItcro or on the first day of life to be useful in neonatal hyperbilirubinaemia (\\'ilson 1972) .
Another factor which will influence drug metabolism, especially in infants and small children, is the high metabolic rate in this age group. If the metabolic pathways are complete and the enzymes present in normal quantities the rate of metabolism will be increased.
Excretion
Renal fUllctiull is immature at birth. Glomerular filtration is :~O-40 per cent less per square metre than the adult, possibly due to lower renal plasma flow (Barnett 19GO) and the smaller pore size in the newborn glomeruli (Grotto 1970) .
Reduced rates of excretion have been found for antibiotics primarily eliminated bv renal mechanisms. The clearance of penicillin" in premature infants was only one-sixth that ohserved in older children when corrected for surface area (Barnett ct al. 1949 ).
Blood levels are highest and plasma half life longest during the first day following the injection of methicillin, ampicillin (Boe et al. 19(7) and oxycillin (Yaffe and Back 196!i) , and gradually decline during the first month. In premature infants the blood levels are even higher and the rate of decline with age is delayed. These antibiotics should therefore be given in relatively lower doses and at less frequent intervals in the newborn.
On the basis of reduced renal function the excretion of most, if not all, drugs which are eliminated unchanged in the urine will be retarded in the early newborn.
Other Factors
(a) Haemoglobin F, which is still present in large amounts in the newborn, is more sensitive to oxidation. This may account for an increased tendency to form methaemoglobinaemia in infants under three months, particularly following the ingestion of drugs like phenacetin and acetanilide (Nyhan and Lampert 19(5) . This raises the question whether infants would be more likely to develop methaemoglobinaemia than adults following use of the local anaesthetic .J Ilacsl/zcsia alld JlItcllsive Carr. 1'01. 1. So. 6, S()vcmber, l!17:J prilocaine. Following epidural anaesthesia with prilocaine for delivery, methaemoglobinaemia developed in both mother and foetus to a comparable level which increased with time from the injection of prilocaine (Peppers and Finster 1968, Arens and Carrera 1970) .
(b) Infants are often treated with vitamin K or its analogues prior to surgery. A syndrome of anaemia, hyperbilirubinaemia and kernicterus has occurred, usually in premature infants, following the administration of high doses (30 mg) of water-soluble derivatives of the vitamin K analogue menadione (Hykinone, Synkavite). Biliburin levels following 1 mg or in infants receiving vitamin K1 (Mephyton) were not greater than controls (Nyhan and Lampert 1965) .
CALCULATION OF DOSAGE
The dose of a drug should be appropriate to the size and the age of the patient. The foregoing discussion of physiological factors affecting pharmacological action during development indicates that a dosage schedule based on proportion of adult dose will be inappropriate, especially in the younger age group. Age is an unsuitable yardstick because of the gross variation in size and weight, but despite this it is often used for the calculation of dosage of common drugs such as aspirin and paracetamol (Panadol). Surface area often gives a more consistent dose throughout the whole age range but requires measurement of height and weight and derivation from a nomogram. It is relatively greater (2! times) in infants compared to body weight than in adults. Calculation on a weight basis is most widely used, and although not ideal it is the most practical. Variations with age from the common dose per kilogram will be necessary for some drugs, particularly in the neonatal period.
The inadvertent administration of an incorrect dose is more likely to occur in paediatric practice due to (1) ignorance of the correct dose-this is a problem particularly in the very young for the reasons already discussed;
(2) the wrong weight being recorded on the chart and the dose being calculated on the incorrect weight -this can often be avoided by assessing the child's weight before prescribing; and (3) an incorrect dose being given.
The causes of these errors are usually carelessness which is avoidable, or ignorance' which can be reduced by an understanding of the differences between children of various ages and adults.
PHARMACOGEXETICS
There are many examples of genetically determined variation in handling of drugs. Genetic factors play an important part in the metabolism of some drugs by the liver, for example there are slow inactivators of isoniazid due to the lack of the enzyme transacetylase (Kalow 1964 , Peters 1968 ). Slow acetylation is a simple Mendelian recessive trait while rapid acetylators are dominant. Several families have been described with members who metabolize diphenylhydantoin (Dilantin) slowly (Kutt 1971) , and a slow metabolizer of salicylate has been described (Levy and Yaffe 1968) . Studies using identical and fraternal twins demonstrated primarily genetic control over large individual differences in rates of halothane biotransformation (Cascorbi et al. 1971) .
Two problems which have aroused particular interest among pharmacogeneticists as well as anaesthetists are the prolonged paralysis following suxamethonium, due to genetically determined pseudocholinesterase variants, and malignant hyperpyrexia.
Other pharmacogenetic diseases of interest to anaesthetists include acute intermittent porphyria, in which barbiturates precipitate acute attacks by inducing the enzyme gamma-amino-levulinic acid synthetase; sickle cell disease where hypoxia and acidosis may cause haemolytic crises, and rare diseases such as myotonia congenita, dystrophia myotonica, and familial dysautonomia. This subject will be reviewed in more detail in a suhsequent paper (Brown and Cass 1973) .
DRUG OVERDOSAGE IN CHILDREK
Overdosage of drugs in the majority of children is accidental except in the older paediatric age group, where a proportion are psychologically disturbed or take them for " kicks". Occasionally a disturbed mother will intentionally overdose her child. About 70-80 per cent of children presenting with drug overdose are under four years of age. The drugs most commonly involved are antidepressants, barbiturates, tranquillizers, iron and salicylates. Some of these patients require management in intensive care units when serious intoxication occurs.
Tricyclic antidepressant overdosage may cause hallucinations, convulsions, coma and cardiac arrhythmias. The convulsions can be controlled with diazqJam (\'alium) or diphenylhydantoin (Dilantin). The arrhythmias can usually be controlled in children by alkalinization with a bolus of J-;3 mEqjkg sodIum bicarbonate (Brown et (It. 1U7; ~) . Studies in rats show that amitriptyline is more toxic in the very young and older rats than those between two to four months (Brmn1 and \\-atson 1973) (Table 2) . Barbiturate O\Tn!osage usually requires maintenance of respiration and the circulation until the drug is eliminated.
Tranquillizer overdosage rarely requires admission to an intensin' care unit. Iron can be very toxic, larger closes causing vomiting and diarrhoea and then, after a latent period, cardiovascular collapse can occur occasionally leading to death. The antidote is the chelating agent, desferrioxamine, which should preferably be gi\'eIl intramuscularly in a dose of 90 mg/kg, which may be repeated in H-12 hours (Chisolm UHO) . Salicylates are more toxic in infants and the occurrence of metabolic acidosis is almost exclusively confined to children under two years. There is evidence that immaturity increases sensitivity to the metabolic but not the respiratory component of salicylate intoxication (Done 19tj~{).
Other uncommon but serious overdoses can occur with orphenidrine (Dissipal), which may cause convulsions and arrhythmias (the latter may respond to sodium bicarbonate administration) and phenirimine (A viI), which may cause tachycardia, arrhythmias and myocardial failure.
The 0 sewrity of drug intoxication can he reduced by inducing vomiting with syrup of ipecac and reducing absorption with activated charcoal. Gastric lavage may be carried out if the patient i~ conscious. III seriou: ;; overdosage with ~oml' of the drugs mentioned above, particularly iron and those causing arrhythmias, efforts should be made to recover the tablets from the stomach. It is important to avoid aspiration during am' attempts at lavage.
